FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

ALSO NOTED: Orchid, Mayne ink marketing deal; Gentium to raise funds; Mylan gets OK for generic Norvasc; and much more...

Tools

> India's Orchid Chemicals and Australia's Mayne Pharma have inked a marketing deal for injectable antibiotics. Report

> Italy's Gentium plans to raise $10.9 million through a private placement. Report

> Mylan Laboratories says it has received final approval for a generic version of Pfizer's Norvasc. Article

And Finally… The FDA is planning a two-day meeting in December to review how it handles drug safety alerts. Article


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about antibiotic   FDA approval   Australia   Mayne Pharma   Biotech deals   Drug Safety   Pfizer   sales and marketing   injectable   India   Generics   private placement   Mylan Laboratories